INmune Bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.9775
- Today's High:
- $8.23
- Open Price:
- $8.07
- 52W Low:
- $5.75
- 52W High:
- $11.258
- Prev. Close:
- $7.97
- Volume:
- 36744
Company Statistics
- Market Cap.:
- $150.57 million
- Book Value:
- 2.823
- Revenue TTM:
- $279000
- Operating Margin TTM:
- -9258.07%
- Gross Profit TTM:
- $374000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -20.5%
- Return on Equity TTM:
- -44.11%
Company Profile
INmune Bio Inc had its IPO on 2019-02-04 under the ticker symbol INMB.
The company operates in the Healthcare sector and Biotechnology industry. INmune Bio Inc has a staff strength of 10 employees.
Stock update
Shares of INmune Bio Inc opened at $8.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.98 - $8.23, and closed at $8.09.
This is a +1.51% increase from the previous day's closing price.
A total volume of 36,744 shares were traded at the close of the day’s session.
In the last one week, shares of INmune Bio Inc have slipped by -3.17%.
INmune Bio Inc's Key Ratios
INmune Bio Inc has a market cap of $150.57 million, indicating a price to book ratio of 2.155 and a price to sales ratio of 306.3056.
In the last 12-months INmune Bio Inc’s revenue was $279000 with a gross profit of $374000 and an EBITDA of $0. The EBITDA ratio measures INmune Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, INmune Bio Inc’s operating margin was -9258.07% while its return on assets stood at -20.5% with a return of equity of -44.11%.
In Q2, INmune Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 187.5%.
INmune Bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into INmune Bio Inc’s profitability.
INmune Bio Inc stock is trading at a EV to sales ratio of 216.5042 and a EV to EBITDA ratio of -3.2469. Its price to sales ratio in the trailing 12-months stood at 306.3056.
INmune Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $69.72 million
- Total Liabilities
- $13.06 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
INmune Bio Inc ended 2024 with $69.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $69.72 million while shareholder equity stood at $50.65 million.
INmune Bio Inc ended 2024 with $0 in deferred long-term liabilities, $13.06 million in other current liabilities, 18000.00 in common stock, $-104051000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $47.83 million and cash and short-term investments were $47.83 million. The company’s total short-term debt was $10,101,000 while long-term debt stood at $4.82 million.
INmune Bio Inc’s total current assets stands at $52.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.05 million compared to accounts payable of $2.39 million and inventory worth $30000.00.
In 2024, INmune Bio Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, INmune Bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $8.09
- 52-Week High
- $11.258
- 52-Week Low
- $5.75
- Analyst Target Price
- $17.33
INmune Bio Inc stock is currently trading at $8.09 per share. It touched a 52-week high of $11.258 and a 52-week low of $11.258. Analysts tracking the stock have a 12-month average target price of $17.33.
Its 50-day moving average was $8.56 and 200-day moving average was $8.04 The short ratio stood at 20.4 indicating a short percent outstanding of 0%.
Around 3506.5% of the company’s stock are held by insiders while 1204.6% are held by institutions.
Frequently Asked Questions About INmune Bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient’s innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer’s disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.